VacZine Analytics  
MarketVIEW: Novel coronavirus [COVID-19] vaccines

To be published: April 2020

The novel coronavirus, SARS-CoV-2 emerged from Wuhan City, Hubei Province of China in late December 2019, causing a cluster of atypical pneumonia cases. The resulting respiratory disease, later referred to as COVID-2019, has been designated by the World Health Organisation (WHO) a Public Health Emergency of International Concern (PHEIC) and a global pandemic. COVID-19 now has affected >175 countries. Many hundreds of thousands will be infected with SARS-CoV-2 with significant excess morbidity, mortality and economic loss. It is debatable, but COVID-19 appears to have a higher naive Case Fatality Ratio (CFR) (~3.4%, WHO figures, based on current data) than seasonal influenza and the human population has little pre-existing immunity. SARS-CoV-2 is related to other coronaviruses such as MERS-CoV, SARS (2003) and human coronaviruses OC43 and 229E which cause the common cold.

Current efforts are now underway to develop new prophylatic vaccines and antiviral therapeutics to address the emergence of SARS-CoV-2. Again, the Coalition of Epidemic Preparedness Innovations (CEPI) is funding numerous new vaccine efforts including the frontrunner, mRNA-1273 being developed by Moderna Therapeutics. which has recently entered Phase I clinical testing. The pursuit of antivirals and other agents is ongoing.

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>225 slides) and 2 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic novel coronavirus vaccine to 2045. The model has three detailed deployment scenarios which include the major Western economies, emerging economies of SE Asia, LATAM and the Far East (63 countries)*. 'At risk' populations or identified target segments (based on latest understanding) are included. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). *15 are rolled up

THIS PRODUCT IS A SUMMARY PRESENTATION (>225 slides, .pdf form) + 2 x FORECAST MODEL(s) (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV086 Click here>> CONTACT US
*This is a licensed product. Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase. Picture Credit: CDC (Unsplash)

Return to main list>> Questions about this report?






© 2020 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains